Email Updates

You are here

Home

3 SEPTEMBER 2021 VOLUME 23 ISSUE 35

Media Coverage

  • New HIV Cases Fell 22 Percent in San Francisco During the Year of COVID-19

    But this could be linked to a decline in HIV testing. Data from 2020 also show a drop in HIV care, especially for homeless San Franciscans.

    September 2, 2021
    General
    POZ

  • NIH on HIV Vaccine Failure: 'Get Your HIV-Negative, At-Risk Patients on PrEP Tomorrow'

    The results [of HVTN 705, known as the Imbokodo study] are frustrating, said Carl Dieffenbach, PhD, director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases (NIAID). To clinicians, Dieffenbach said the message of this HIV vaccine trial is flush with urgency: "Get your HIV-negative, at-risk people on PrEP tomorrow."

    September 2, 2021
    HIV Vaccine, PrEP
    Medscape

  • What Will it Take to Bring HIV Prevention Injections to South Africa's Clinics?

    Sibongile Tshabalala, National Chairperson of the Treatment Action Campaign (TAC) tells Spotlight that groups they consult with all would prefer an injection over a pill (oral PrEP]. “They ask us how long are we going to wait to have access to it?”

    September 1, 2021
    PrEP
    Spotlight

  • Will the Moderna HIV Vaccine Trials Succeed?

    On August 11, Moderna, the biotech company behind one of the COVID-19 vaccines, posted a study record announcing that they were set to start Phase 1 of human trials on a HIV mRNA vaccine. These trials will consist of 56 adults between the ages of 18 to 50 years old who don't have HIV and test for safety, immune responses and antibodies.

    September 1, 2021
    HIV Vaccine
    Paper

  • An Experimental HIV Vaccine Fails in Africa

    An advanced HIV vaccine trial in Africa has been shut down after data showed the shots offered only limited protection against the virus, researchers announced on Tuesday. The vaccine, made by Johnson & Johnson, is one in a long line found to offer little defense against HIV, one of medicine’s most intractable adversaries.

    August 31, 2021
    HIV Vaccine
    New York Times

  • J&J Halts Africa HIV Vaccine Trial as Prevention Falls Short

    Johnson & Johnson stopped a mid-stage test of its HIV vaccine in southern Africa after the shot showed insufficient ability to protect people from contracting the virus. The trial, called Imbokodo, showed the vaccine was just 25 percent effective in preventing HIV infection over a period of two years, short of a goal of 50% efficacy, according to a statement. A similar vaccine developed by the drugmaker will continue being tested in Europe and the Americas in a final-stage study called Mosaico, Paul Stoffels, J&J’s chief scientific officer, said.

    August 31, 2021
    HIV Vaccine
    Bloomberg

  • Could Gene Therapies Be Used To Cure More People With HIV?

    Medical science is starting to license and use drugs and procedures that change the genetic code inside the body’s cells, and to correct the ‘bad code’ that can give rise to conditions such as cancer and the auto-immune diseases. Since HIV is a disease that results from a virus inserting such a piece of bad code into our genes, such therapies could be used to snip out that code and effect a cure.

    August 31, 2021
    Cure
    aidsmap

  • HIV Combination Prevention Associated with Sharp Drop in Diagnoses

    A combination of HIV prevention methods—including pre-exposure prophylaxis (PrEP), early HIV diagnosis through frequent testing and timely antiretroviral therapy for treatment as prevention – was associated with a sharp drop in HIV transmission among gay, bisexual and other men who have sex with men, a new study found.

    August 31, 2021
    Combination Prevention
    Contagion Live

  • Failed HIV Vaccine Trial Marks Another Setback for the Field

    A Johnson & Johnson vaccine only offered hints of protection in women in five sub-Saharan Africa countries.

    August 31, 2021
    HIV Vaccine
    Science

  • Left Your PrEP Appointment Without a Prescription? HIV Risk May Double

    If you’re not white, male and older than 25, the health care system needs to do a whole lot better to enable you take and stay on HIV PrEP, according to a study published in JAMA Network Open.

    August 31, 2021
    PrEP
    POZ

  • How To Speed-Up PrEP Rollout in Sub-Saharan Africa

    An evidence review has identified the main gaps in health systems in sub-Saharan Africa that need to be addressed to boost PrEP (pre-exposure prophylaxis) scale-up.

    August 30, 2021
    PrEP
    Avert

  • How the Black Church Can Help End the HIV/AIDS Crisis

    On this National Faith HIV/AIDS Awareness Day, the HIV/AIDS epidemic remains a looming threat to Black communities. Decades of silence, stigma and structural barriers to treatment and testing have allowed the epidemic to spread, claiming the lives of far too many of our Black friends and families.

    August 30, 2021
    General
    Washington Post

  • Fast-Track Drug Refills Prove the Most Common HIV Service Adaptation in Uganda

    Healthcare providers and people with HIV in Uganda prefer clinic-based models of simplified HIV care to community-based models, Ugandan researchers report.... Convenience, confidentiality and contact with healthcare workers were judged more important to clients, so that clinic-based drug refill had been more widely adopted than other forms of differentiated service delivery, the study found.

    August 30, 2021
    Treatment
    aidsmap

  • Research Round-Up: Seven New HIV Prevention Options in the Pipeline

    One of the most vibrant areas of HIV research these days is the search for new, more convenient ways to use antiretrovirals to prevent HIV infection. The latest advances in the field — including a biodegradable antiretroviral implant — were presented at a recent International AIDS Society Conference.

    August 27, 2021
    PrEP
    Daily Maverick

  • Uganda to Re-consider Problematic HIV Law Provisions

    After five years of waiting, the Constitutional Court of Uganda has finally begun to hear a landmark case challenging the overly broad and draconian provisions of the HIV and AIDS Prevention and Control Act of 2014.

    August 27, 2021
    General
    HIV Justice Network

Published Research

Announcements